In ovarian cancer (SK-OV-3 and OVCAR3) and esophageal squamous cell carcinoma (KYSE150 and KYSE510) cells, EGCG induces apoptosis by increasing the levels of pro-apoptotic proteins (Bax and Cytochrome c), activating Caspase-3 and Caspase-9, and stimulating tumor suppressor genes (PTEN and SERPINB2), while simultaneously decreasing the expression of anti-apoptotic proteins (Bcl-2 and Bcl-xL) [559, 560]. The gene discussed is BCL2; the disease is ovarian carcinoma.